0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Invited Commentary | 
Hillary V. Kunins, MD, MPH, MS
JAMA Intern Med. 2015;175(6):987-988. doi:10.1001/jamainternmed.2015.0939.

Original Investigation | 
Marc R. Larochelle, MD, MPH; Fang Zhang, PhD; Dennis Ross-Degnan, ScD; et al.
JAMA Intern Med. 2015;175(6):978-987. doi:10.1001/jamainternmed.2015.0914.
Includes: CME, Supplemental Content

Original Investigation | 
Matthew Miller, MD, ScD; Catherine W. Barber, MPA; Sarah Leatherman, PhD; et al.
JAMA Intern Med. 2015;175(4):608-615. doi:10.1001/jamainternmed.2014.8071.
Includes: Supplemental Content

Original Investigation | 
Wayne A. Ray, PhD; Cecilia P. Chung, MD, MPH; Katherine T. Murray, MD; et al.
JAMA Intern Med. 2015;175(3):420-427. doi:10.1001/jamainternmed.2014.6294.
Includes: Supplemental Content

Research Letter | 
Michael A. Yokell, ScB; M. Kit Delgado, MD, MS; Nickolas D. Zaller, PhD; et al.
JAMA Intern Med. 2014;174(12):2034-2037. doi:10.1001/jamainternmed.2014.5413.

Invited Commentary | 
Marie J. Hayes, PhD; Mark S. Brown, MD
JAMA Intern Med. 2014;174(10):1673-1674. doi:10.1001/jamainternmed.2014.2716.

Original Investigation | 
Marcus A. Bachhuber, MD; Brendan Saloner, PhD; Chinazo O. Cunningham, MD, MS; et al.
JAMA Intern Med. 2014;174(10):1668-1673. doi:10.1001/jamainternmed.2014.4005.

Invited Commentary | 
Margot Kushel, MD
JAMA Intern Med. 2014;174(8):1377-1378. doi:10.1001/jamainternmed.2014.728.

Invited Commentary | 
Jeffrey Brent, MD, PhD
JAMA Intern Med. 2014;174(6):918-919. doi:10.1001/jamainternmed.2014.19.

Original Investigation |  FREE
Laura Conklin, MD; James J. Sejvar, MD; Stephanie Kieszak, MA, MPH; et al.
JAMA Intern Med. 2014;174(6):912-917. doi:10.1001/jamainternmed.2014.344.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Brief Report  | 
Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib
Kenar D. Jhaveri, MD; Vipulbhai Sakhiya, MBBS; Steven Fishbane, MD
JAMA Oncology
Invited Commentary  | 
JAK/STAT Pathway Inhibitors and Neurologic Toxicity: Above All Else Do No Harm?
Bart L. Scott, MD; Pamela S. Becker, MD, PhD
JAMA Oncology
Original Investigation  | 
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial
Animesh Pardanani, MD; Claire Harrison, MD; Jorge E. Cortes, MD; et al.
JAMA
Medical News & Perspectives  | 
Margaret A. Hamburg, MD, Reflects on 6 Years at FDA
Rita Rubin, MA